Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Astellas Gene Therapies, Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is concentrated under 1 distinct examiner and 1 distinct art unit, indicating a focused prosecution footprint at this stage. The concentration of work suggests that the company's current interactions with the USPTO are limited to a specific niche or a single active application.
The busiest examiner for the portfolio is ALLEN, MICHAEL D, who is responsible for 1 pending office action. Because the total number of pending office actions is also 1, this examiner handles the entirety of the company's current workload. This alignment between the busiest examiner and the total pending actions reflects a lack of examiner variety in the current pipeline.
Practitioners should note that the outcome of this single office action will define the immediate success rate for the portfolio in this technology area. The presence of a single distinct art unit and examiner further confirms that the prosecution is not currently spread across different specialized groups within the USPTO. This allows the legal team to focus on the procedural requirements and substantive preferences of a single examiner rather than managing multiple conflicting timelines.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287963 | TISSUE-TARGETED MODIFIED AAV CAPSIDS AND METHODS OF USE THEREOF | ALLEN, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287963 | TISSUE-TARGETED MODIFIED AAV CAPSIDS AND METHODS OF USE THEREOF | ALLEN, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287963 | TISSUE-TARGETED MODIFIED AAV CAPSIDS AND METHODS OF USE THEREOF | ALLEN, MICHAEL D | 1671 | §103§112 | Non-Final OA | — | Pending | Oct 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAstellas Gene Therapies, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael D Allen has the most, with 1 of Astellas Gene Therapies, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
